BR112015019264A2 - composições farmacêuticas para o tratamento de helicobacter pylori - Google Patents

composições farmacêuticas para o tratamento de helicobacter pylori

Info

Publication number
BR112015019264A2
BR112015019264A2 BR112015019264A BR112015019264A BR112015019264A2 BR 112015019264 A2 BR112015019264 A2 BR 112015019264A2 BR 112015019264 A BR112015019264 A BR 112015019264A BR 112015019264 A BR112015019264 A BR 112015019264A BR 112015019264 A2 BR112015019264 A2 BR 112015019264A2
Authority
BR
Brazil
Prior art keywords
treatment
pharmaceutical compositions
helicobacter pylori
pylori
infection
Prior art date
Application number
BR112015019264A
Other languages
English (en)
Other versions
BR112015019264B1 (pt
BR112015019264A8 (pt
Inventor
Raday Gilead
Goldberg Guy
Gosselin Patrick
Fathi Reza
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51297592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015019264(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of BR112015019264A2 publication Critical patent/BR112015019264A2/pt
Publication of BR112015019264A8 publication Critical patent/BR112015019264A8/pt
Publication of BR112015019264B1 publication Critical patent/BR112015019264B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

resumo patente de invenção: "composições farmacêuticas para o tratamento de helicobacter pylori". uma forma de dosagem sólida oral simples compreendendo uma primeira composição de dosagem de liberação imediata tendo pelo menos dois agentes antibióticos e uma segunda composição de dosagem de liberação retardada tendo um inibidor de bomba de prótons é aqui provida. a forma de dosagem sólida oral simples de acordo com alguns aspectos da invenção pode ser usada para o tratamento de distúrbios associados com infecção por h. pylori ou a prevenção de recorrência de distúrbios associados com infecção por h. pylori.
BR112015019264-5A 2013-02-13 2014-02-12 Cápsulas para o tratamento de helicobacter pylori e seu uso BR112015019264B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361764401P 2013-02-13 2013-02-13
US201361764385P 2013-02-13 2013-02-13
US61/764,385 2013-02-13
US61/764,401 2013-02-13
PCT/US2014/016071 WO2014127025A1 (en) 2013-02-13 2014-02-12 Pharmaceutical compositions for the treatment of helicobacter pylori

Publications (3)

Publication Number Publication Date
BR112015019264A2 true BR112015019264A2 (pt) 2017-07-18
BR112015019264A8 BR112015019264A8 (pt) 2019-11-12
BR112015019264B1 BR112015019264B1 (pt) 2021-08-24

Family

ID=51297592

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015019264-5A BR112015019264B1 (pt) 2013-02-13 2014-02-12 Cápsulas para o tratamento de helicobacter pylori e seu uso

Country Status (26)

Country Link
US (7) US9050263B2 (pt)
EP (1) EP2956149B1 (pt)
JP (1) JP6494529B2 (pt)
KR (1) KR102062357B1 (pt)
CN (2) CN105163743A (pt)
AU (1) AU2014216373B2 (pt)
BR (1) BR112015019264B1 (pt)
CA (1) CA2900763C (pt)
CL (1) CL2015002253A1 (pt)
CY (1) CY1122113T1 (pt)
DK (1) DK2956149T3 (pt)
ES (1) ES2744406T3 (pt)
HK (1) HK1217645A1 (pt)
HR (1) HRP20191559T1 (pt)
HU (1) HUE052411T2 (pt)
IL (1) IL240387B (pt)
MX (1) MX368536B (pt)
NZ (1) NZ711754A (pt)
PH (1) PH12015501783B1 (pt)
PL (1) PL2956149T3 (pt)
PT (1) PT2956149T (pt)
RU (1) RU2671400C2 (pt)
SG (1) SG11201506318QA (pt)
SI (1) SI2956149T1 (pt)
UA (1) UA120249C2 (pt)
WO (1) WO2014127025A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2744406T3 (es) 2013-02-13 2020-02-25 Redhill Biopharma Ltd Composiciones farmacéuticas para el tratamiento de helicobacter pylori
KR101884230B1 (ko) * 2016-02-29 2018-08-01 주식회사 유영제약 에소메프라졸을 포함하는 제제
JP2018149269A (ja) * 2017-01-18 2018-09-27 マッカイ メディカル ファンデーション ザ プレスビュテロス チャーチ イン タイワン マッカイ メモリアル ホスピタル 消化管感染症に対する管腔内治療システム
AU2018348777A1 (en) * 2017-10-15 2019-07-11 Centre For Digestive Diseases Compositions and methods for treating, ameliorating and preventing H. pylori infections
CN108497546B (zh) * 2018-03-22 2021-03-19 宝可科技（上海）有限公司 一种烟用添加剂及其制备方法和用途
CN110354125A (zh) * 2019-08-12 2019-10-22 珠海赛隆药业股份有限公司 一种治疗幽门螺杆菌感染的组合物及其制剂和用途
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index
KR20230151483A (ko) * 2022-04-22 2023-11-01 한국생명공학연구원 헬리코박터 파일로리 감염의 예방 또는 치료용 유효성분의 스크리닝 플랫폼
CN117398360B (zh) * 2023-12-14 2024-03-15 山东齐都药业有限公司 治疗幽门螺杆菌的复方制剂胶囊及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980637A (en) * 1975-03-17 1976-09-14 Bristol-Myers Company Production of amoxicillin
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
CA2271799A1 (en) 1996-11-22 1998-05-28 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
SE9700885D0 (sv) 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
AUPP325398A0 (en) * 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
US5927500A (en) * 1998-06-09 1999-07-27 Milliken & Company Pharmaceutical containment package
JP2000128779A (ja) * 1998-10-20 2000-05-09 Mitsui Chemicals Inc 薬物放出制御型製剤
US20040213847A1 (en) * 2003-04-23 2004-10-28 Matharu Amol Singh Delayed release pharmaceutical compositions containing proton pump inhibitors
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
EP1803450A1 (en) * 2006-01-03 2007-07-04 Ferrer Internacional, S.A. Pharmaceutical compositions for the eradication of helicobacter pylori
WO2009008005A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
JP5260905B2 (ja) 2007-07-12 2013-08-14 株式会社ジャパンディスプレイ 有機ｅｌ表示装置
JP5032577B2 (ja) 2007-07-20 2012-09-26 興和株式会社 鉛濃度測定用試薬及び鉛濃度測定方法
WO2009017716A2 (en) 2007-07-27 2009-02-05 Depomed, Inc. Pulsatile gastric retentive dosage forms
CN101584681A (zh) * 2008-05-23 2009-11-25 黑龙江福和华星制药集团股份有限公司 一种用于治疗幽门螺旋杆菌感染的片剂胶囊
CN101607086B (zh) * 2009-07-21 2011-11-02 山西安特生物制药股份有限公司 一种复方铋剂组合物及其制备方法
CN102091084B (zh) * 2010-12-09 2012-05-09 王勇 一种复方胶囊及其制备方法
ES2744406T3 (es) * 2013-02-13 2020-02-25 Redhill Biopharma Ltd Composiciones farmacéuticas para el tratamiento de helicobacter pylori

Also Published As

Publication number Publication date
EP2956149A4 (en) 2016-10-12
SG11201506318QA (en) 2015-09-29
IL240387B (en) 2020-02-27
CN105163743A (zh) 2015-12-16
PT2956149T (pt) 2019-09-20
US11135172B2 (en) 2021-10-05
WO2014127025A1 (en) 2014-08-21
BR112015019264B1 (pt) 2021-08-24
AU2014216373A1 (en) 2015-08-27
SI2956149T1 (sl) 2019-11-29
JP2016508516A (ja) 2016-03-22
NZ711754A (en) 2020-05-29
US20140227353A1 (en) 2014-08-14
RU2015138708A (ru) 2017-03-17
CA2900763C (en) 2021-04-06
HK1217645A1 (zh) 2017-01-20
MX368536B (es) 2019-10-07
ES2744406T3 (es) 2020-02-25
DK2956149T3 (da) 2019-09-09
MX2015010490A (es) 2015-10-30
BR112015019264A8 (pt) 2019-11-12
CA2900763A1 (en) 2014-08-21
HUE052411T2 (hu) 2021-04-28
US9603806B2 (en) 2017-03-28
IL240387A0 (en) 2015-09-24
US10898439B2 (en) 2021-01-26
US11931463B2 (en) 2024-03-19
US20150044283A1 (en) 2015-02-12
HRP20191559T1 (hr) 2019-11-29
US20220062188A1 (en) 2022-03-03
US20190175512A1 (en) 2019-06-13
US9498445B2 (en) 2016-11-22
US20190336451A1 (en) 2019-11-07
RU2671400C2 (ru) 2018-10-31
UA120249C2 (uk) 2019-11-11
US20170189341A1 (en) 2017-07-06
CN109893516A (zh) 2019-06-18
KR20150118176A (ko) 2015-10-21
PH12015501783A1 (en) 2015-12-07
CL2015002253A1 (es) 2016-07-29
US10238606B2 (en) 2019-03-26
PL2956149T3 (pl) 2020-03-31
US9050263B2 (en) 2015-06-09
KR102062357B1 (ko) 2020-01-03
CY1122113T1 (el) 2020-11-25
PH12015501783B1 (en) 2015-12-07
JP6494529B2 (ja) 2019-04-03
EP2956149A1 (en) 2015-12-23
US20160235681A1 (en) 2016-08-18
EP2956149B1 (en) 2019-06-19
AU2014216373B2 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
BR112015019264A2 (pt) composições farmacêuticas para o tratamento de helicobacter pylori
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
DOP2017000137A (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo.
BR112018013227A2 (pt) ?composições farmacêuticas ou kit para o uso, métodos para tratar câncer em um mamífero e uso de uma composição?
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
BR112018070852A2 (pt) composições de dissulfeto de selênio para uso no tratamento de disfunção das glândulas meibomianas
EA201890842A1 (ru) Комбинация гликозаминогликанов и антацидного агента и содержащие их композиции
AR094374A1 (es) Composiciones y métodos para el tratamiento de trastornos metabólicos
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
EA201991387A1 (ru) ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ
BR112015018827A2 (pt) composição farmacêutica oral para tratamento de mucosite oral e estomatite
BR112019005985A2 (pt) composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico
BR112018000786A2 (pt) métodos e composições usando bifidobacterium longum para modular a reatividade emocional e tratar ou evitar perturbações subclínicas do estado de humor
BR112019004684A2 (pt) combinação de agonistas de fxr
BR112017016497A2 (pt) composições e métodos para metabolismo muscular melhorado
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
BR112015023368A2 (pt) método de tratamento de deficiência de vitamina b12
BR112015030350A2 (pt) forma de dosagem farmacêutica oralmente administrável para uso na prevenção e/ou no tratamento de uma doença cardiovascular
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
EA202090666A1 (ru) Применение содержащей бензоат композиции для лечения глициновой энцефалопатии
BR112016008035A8 (pt) composição, uso da composição
MX2018011142A (es) Combinacion farmaceutica sinergica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona.
BR112019002213A2 (pt) composições e o uso das mesmas para tratar ou prevenir rosácea
BR112018011138A2 (pt) formulações para administração intravenosa

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/02/2014, OBSERVADAS AS CONDICOES LEGAIS.